Relay Therapeutics, Inc.: SB INVESTMENT ADVISERS (UK) LTD amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
SB Investment Advisers (UK) Ltd amended its Schedule 13G filing on Relay Therapeutics, disclosing a change in its beneficial ownership stake in the clinical-stage biotech. The filing, submitted under SEC accession 0001493152-26-052668, updates the investment adviser's position after its prior disclosure. The amendment matters because 13G updates signal shifts in institutional ownership that can influence Relay's shareholder base and governance dynamics. Investors should watch for the specific share count and percentage disclosed in the amended filing, and whether further 13G or 13D activity follows from other large holders.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Relay Therapeutics, Inc., SB Investment Advisers (UK) Ltd